About US
Contact us
-
ASCO: Gilead touts CAR-T franchise with Yescarta analyses, early data on pipeline drugAs other parts of its business slump, Gilead Sciences has zeroed in on cell therapy, hoping to lead a wave into that new market. And at the American Society of Clinical Oncology's (ASCO's) annual m2019/5/30
-
All the ASCO skinny: Lynparza's pancreatic win, Amgen's KRAS spotlight, Merck's history-busting and moreThe cancer world flocked to Chicago over the weekend for what's traditionally been the biggest oncology meet-up of the year. But this year's American Society of Clinical Oncology line-up didn't exact2019/5/29
-
ASCO: AZ, Merck's Lynparza fends off pancreatic cancer, cutting progression risk in halfCHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology (ASCO) annual meeting—and doing it in some of the toughest-to-trea2019/5/29
-
Four pharma firms accused of anti-competitive practices in UKThe UK Competition and Markets Authority (CMA) has accused Alliance Pharmaceuticals, Focus, Lexon and Medreich of avoiding competition for anti-nausea drug, prochlorperazine. Indicated for the treatm2019/5/28
-
Lilly starts selling half-price version of Humalog insulinEli Lilly has announced the market launch of a half-price, generic version of its Humalog insulin. Called Insulin Lispro Injection, the product is available in a vial or within a KwikPen. Insulin Lis2019/5/28
-
Chugai Pharmaceutical to build new $1bn research lab in JapanChugai Pharmaceutical has revealed plans to establish a core research laboratory at its business site in Yokohama, Kanagawa Prefecture, Japan. Named Chugai Life Science Park Yokohama, the new facilit2019/5/27
-
Janssen’s Invokana secures FDA priority review statusJanssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney dise2019/5/27
-
Novartis CEO says Zolgensma won't cost anywhere near the $4M to $5M once quotedNovartis has said its forthcoming spinal muscular atrophy gene therapy could be cost-effective at a price of up to $5 million, but now the company's CEO says to think "far lower." As the Swiss drug2019/5/24
-
Array's ‘extremely compelling’ new colon cancer data spark blockbuster talkThe news that Array BioPharma’s clinical trial of its triplet therapy for colon cancer extended lives in a trial of patients with the BRAF mutation sent the company’s shares up 23% on Tuesday—a run t2019/5/24
-
GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle ChinaGlaxoSmithKline’s shingles vaccine Shingrix has continuously impressed industry watchers with its explosive growth. Now, the company has added another large market to its list:China. Shingrix has bee2019/5/23